Physician profile
Albert A Cook
NPI 1891729430
$330,969.15
in general payments reported to CMS, 2019-2025
39 companies · $54K in 2025
The $54K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109K · 2020: $7,125 · 2021: $1,703 · 2022: $96K · 2023: $25K · 2024: $38K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Travel and Lodging: $10K · Consulting Fee: $5,300 · Food and Beverage: $5,123 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $96,725.00 |
| Travel and Lodging | $10,321.00 |
| Consulting Fee | $5,300.00 |
| Food and Beverage | $5,123.49 |
| Education | $132.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $236,083.56 | 2019-2025 | Hizentra |
| Argenx US, INC. | $78,653.00 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $5,212.89 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $3,250.95 | 2019-2025 | |
| Abbott Laboratories | $853.90 | 2020 | |
| Alexion Pharmaceuticals, INC. | $768.05 | 2019-2025 | Ultomiris, Soliris |
| Biogen, INC. | $619.93 | 2019-2025 | Tysabri, Spinraza |
| Teva Pharmaceuticals USA, INC. | $582.31 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Genzyme Corporation | $579.70 | 2019-2023 | |
| Abbvie INC. | $534.12 | 2019-2025 | Ubrelvy |
| E.R. Squibb & Sons, L.L.C. | $517.16 | 2020-2024 | Zeposia |
| Emd Serono, INC. | $395.48 | 2019-2021 | |
| Janssen Biotech, INC. | $334.67 | 2025 | |
| Ucb, INC. | $327.25 | 2019-2025 | Rystiggo |
| Amgen INC. | $322.18 | 2019-2025 | Uplizna |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.